Skip to main content
Caplight Logo









Helperby Therapeutics

Helperby Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.helperby.com/

Last Round

Strategic

Mar 17, 2025

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Helperby Therapeutics is a biopharmaceutical company that develops novel antibiotic combination therapies to combat antimicrobial resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antimicrobial resistanceAMRantibiotic resistance breakersARBsuperbugcombination therapybiopharmaceuticaldrug discoveryvirtual biotechmultidrug-resistant bacteriaclinical-stagesmall molecule drugbiofilm infectionsout-licensingGram-negative bacteria

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Helperby Therapeutics Comparables

Compare Helperby Therapeutics with similar companies based on industry and business-model similarity.

Helperby Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AdjuTec Pharma AS
87%
VenatoRx Pharmaceuticals
84%
QureTech Bio
82%

Helperby Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMar 17, 2025

Key People

Founding team and executive leadership

FRCP Sir Anthony Milnes Coates BSc

Founder and Chief Scientific Officer

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 30% MoM.

  • Jul 25, 2026

    Monthly visitors increased 452% MoM, reaching 1.1K.

Helperby Therapeutics Filings

Explore SEC and related filing metadata, where available.

Helperby Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Helperby Therapeutics's valuation, stock price, and market status.

Is Helperby Therapeutics a public or private company?

Helperby Therapeutics is a private company.

What is the current stock price of Helperby Therapeutics?

Helperby Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Helperby Therapeutics worth (valuation)?

Valuation information for Helperby Therapeutics is not publicly available.

Can I buy Helperby Therapeutics stock?

Helperby Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Helperby Therapeutics's last funding round?

Helperby Therapeutics's most recent funding round was Strategic on March 17, 2025.

Who are the main investors in Helperby Therapeutics?

Investor information for Helperby Therapeutics is not publicly disclosed.

Will Helperby Therapeutics IPO soon?

No public IPO plans have been announced for Helperby Therapeutics.

How can I track Helperby Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Helperby Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range7
Year Founded2002
Last FundingMar 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?